Home » ALBANY MOLECULAR RESEARCH, INC. ANNOUNCES LICENSING DEAL WITH BRISTOL-MYERS SQUIBB COMPANY
ALBANY MOLECULAR RESEARCH, INC. ANNOUNCES LICENSING DEAL WITH BRISTOL-MYERS SQUIBB COMPANY
Albany Molecular Research, Inc. (Nasdaq: AMRI) today announced a licensing agreement
with Bristol-Myers Squibb (NYSE: BMY) for its broad program of compounds that
encompass biogenic amine reuptake inhibitors in development for the treatment
of depression and other central nervous system disorders.
Under the terms of
the agreement, Bristol-Myers Squibb will receive an exclusive license to develop
and commercialize multiple potential products from AMRI's proprietary amine
neurotransmitter reuptake inhibitors identified in one of AMRI's proprietary
research programs.
Genetic
Engineering News
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May